Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC
| Autor: | Swati B. Gupta, Charles J. Robbins, David L. Rimm, Jon Zugazagoitia, Wei Wei, Deborah B. Doroshow, Blythe J.S. Adamson |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
Oncology medicine.medical_specialty Lung Neoplasms Pembrolizumab Antibodies Monoclonal Humanized B7-H1 Antigen Article Carcinoma Non-Small-Cell Lung Proto-Oncogene Proteins Internal medicine PD-L1 medicine ROS1 Clinical endpoint Overall survival Humans In patient Immune Checkpoint Inhibitors Aged Retrospective Studies biology business.industry Histology Protein-Tyrosine Kinases Cohort biology.protein business |
| Zdroj: | J Thorac Oncol |
| ISSN: | 1556-0864 |
| DOI: | 10.1016/j.jtho.2021.07.032 |
| Popis: | BACKGROUND: For patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors, PD-L1 tumor proportion score has been validated as a predictive biomarker for improved overall survival. However, its histology-specific predictive value in patients with advanced squamous versus nonsquamous cancers remains unclear. PURPOSE: To assess the differential value of PD-L1 tumor proportion score (TPS) as a predictive biomarker for overall survival after first-line pembrolizumab in patients with squamous versus nonsquamous NSCLC. BASIC PROCEDURES: Retrospective, observational study of patients diagnosed with advanced NSCLC who were treated between October 2015 and April 2019 at community oncology clinics and academic medical centers in a de-identified EHR-derived database. Included patients were diagnosed with advanced or metastatic NSCLC, received treatment with first-line, single agent pembrolizumab, and had documentation of PD-L1 testing with a numeric result. Exclusion criteria included alterations in EGFR, ALK, and ROS1.The primary endpoint was overall survival from start of first-line pembrolizumab therapy by squamous or nonsquamous histology and PD-1 expression level measured by TPS (low |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|